CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Down 40.1% in November

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 683,300 shares, a decline of 40.1% from the October 31st total of 1,140,000 shares. Based on an average daily volume of 14,840,000 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CNS Pharmaceuticals stock. Virtu Financial LLC increased its holdings in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 616.6% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 94,246 shares of the company’s stock after buying an additional 81,094 shares during the period. Virtu Financial LLC owned 0.80% of CNS Pharmaceuticals worth $34,000 as of its most recent SEC filing. Institutional investors and hedge funds own 14.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Maxim Group upgraded CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research note on Tuesday, September 10th.

CNS Pharmaceuticals Price Performance

Shares of CNSP stock remained flat at $0.12 during trading hours on Thursday. 2,049,487 shares of the stock were exchanged, compared to its average volume of 5,683,426. The stock has a 50 day simple moving average of $0.13 and a two-hundred day simple moving average of $1.83. The firm has a market capitalization of $6.63 million, a price-to-earnings ratio of 0.00 and a beta of 2.58. CNS Pharmaceuticals has a one year low of $0.10 and a one year high of $116.00.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.